TEJ-KOHLI-FOUNDATION
The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capital will be available to both commercial and non-commercial projects that have a clear path to the prevention, treatment and cure of corneal blindness; with funding decisions based on the magnitude of the total impact that a project will likely have in poor and underserved communities worldwide by 2035, as well as the likelihood that a project will succeed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200221005010/en/
The Tej Kohli Foundation continues to build its position as a multi-disciplinary global centre of focus for the development and advancement of an affordable, scalable and accessible ‘universal solution’ for preventing and eliminating corneal blindness. The World Health Organisation says that 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. Whilst approximately 75% of corneal disease is curable by corneal transplant, the costs of invasive surgery, and the many years of medicine needed to prevent rejection after surgery, makes this form of treatment entirely inaccessible to the majority of the people in the world who suffer from severe visual impairment or corneal blindness.
Tej Kohli co-founded the eponymous Foundation in 2005 alongside wife Wendy Kohli. He has previously spoken about funding life-changing corneal transplants in poor and underserved communities as being “like Schindler’s List, you do a few, then you just have to do more” (https://www.telegraph.co.uk/technology/2019/10/04/tej-kohli-indian-tech-billionaire-plans-turbocharge-britains/ ). In December 2019 the Tej Kohli Foundation announced that it had restored the sight of 5,736 blind people during the year (https://www.businesswire.com/news/home/20191219005417/en/5736-World%E2%80%99s-Poorest-People-Received-Gift-Sight ) and committed $14m of further funding to its Cornea Institute.
Tej Kohli is also an evangelist of the opportunities that can be derived from the chain reaction of technological progression and the impact that they can have on human life: https://www.spearswms.com/billionaire-philanthropist-tej-kohli-ai/ . The new Tej Kohli Foundation incubator hopes to back projects that can leverage this chain reaction of technological progression to develop and deliver new techniques and applications and game-changing innovations for improving access. The Foundation is seeking to incubate between one and three new projects initially, and welcomes funding applications from all fields of expertise. Projects must show that they can make a significant impact by 2035.
The Tej Kohli Foundation funded its first donor cornea implants at Niramaya Hospital in India in 2010. After funding thousands of corneal transplants, in 2015 the Tej Kohli Foundation substantially expanded its efforts to tackle corneal blindness in poor and underserved communities with the ambitious launch the Tej Kohli Cornea Institute in Hyderabad. Between January 2016 and November 2019 the Tej Kohli Cornea Institute welcomed more than 223,404 outpatients and completed more than 43,255 surgical procedures. The Tej Kohli Foundation has also pursued a ‘universal treatment’ for corneal blindness through its ‘Applied Research’ program, which is a longstanding scientific collaboration between researchers in Montreal Canada, and Moorfields Eye Hospital in the UK.
In January 2020 seed funding from the Tej Kohli Foundation was granted to two new research projects. The first project will focus on preventing corneal endothelial cell loss, which is usually permanent and is the leading reason for corneal transplantation worldwide. The second project will use novel drugs released by contact lenses to treat ocular surface pain and overcome the need for opioids when treating severe eye pain, which remains one of the unmet needs in Ophthalmology.
Eligible projects are invited to submit a 2-page project abstract as a PDF to: project2035@tejkohlifoundation.com . Submissions will be considered by the Tej Kohli Foundation on a case-by-case basis in direct collaboration with its global network of specialists.
Wendy Kohli, co-Founder of the Tej Kohli Foundation said:
“The YouTube channel of the Tej Kohli Foundation has many stories of individuals who have been cured of severe visual impairment or corneal blindness. But the overwhelming majority of those living needlessly with blindness still cannot afford or access treatment. It is only through major innovations borne from research, science, technology and enterprise that we can move toward a world where nobody is needlessly blind because of poverty.”
Tej Kohli, co-Founder of the Tej Kohli Foundation said:
“There are many innovations already in the pipeline that could one day offer affordable, scalable and accessible solutions for prevention and cure in the poor and underserved communities where corneal blindness is most pervasive. At the Tej Kohli Foundation we are interested in backing and funding new innovations and projects that will accelerate progress toward the goal of eliminating poverty-driven corneal blindness worldwide by 2035.”
About the Tej Kohli Foundation:
Website: http://www.tejkohlifoundation.com
YouTube: https://www.youtube.com/c/tejkohlifoundation
About Tej Kohli:
Profile: https://www.tejkohlifoundation.com/tej-kohli
Twitter: https://twitter.com/mrtejkohli
About Wendy Kohli:
Profile: https://www.tejkohlifoundation.com/wendy-kohli
View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005010/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q
Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release
Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r
Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset
Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release
Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
